Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
List view / Grid view
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
The designers of the Dual Chimeric Antigen Receptor (CAR) T cell therapy report it slows HIV replication and leads to a smaller viral reservoir in HIV-infected mice.
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
Scientists have developed a synthetic biology process using enzymes to create three families of terpenes, potential starting points for new drugs.
A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
A molecule called TPPU has been shown to inhibit an enzyme that plays a key role in inflammation, successfully treating arthritis in mice.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
A study in older mice with type 2 diabetes revealed a tuberculosis vaccine elicited a strong immune response, making it a promising candidate for the condition.
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
An α-radioimmunotherapy called 212Pb-anti-CD38 was effective at preventing tumour growth and increasing survival in multiple myeloma tumour-bearing mice, a study has shown.